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Background. Lack of coordination between screening studies for common mental disorders in primary care and
community epidemiological samples impedes progress in clinical epidemiology. Short screening scales based on the
World Health Organization (WHO) Composite International Diagnostic Interview (CIDI), the diagnostic interview
used in community epidemiological surveys throughout the world, were developed to address this problem.
Method. Expert reviews and cognitive interviews generated CIDI screening scale (CIDI-SC) item pools for 30-day
DSM-IV-TR major depressive episode (MDE), generalized anxiety disorder (GAD), panic disorder (PD) and bipolar
disorder (BPD). These items were administered to 3058 unselected patients in 29 US primary care oﬃces. Blinded
SCID clinical reinterviews were administered to 206 of these patients, oversampling screened positives.
Results. Stepwise regression selected optimal screening items to predict clinical diagnoses. Excellent concordance
[area under the receiver operating characteristic curve (AUC)] was found between continuous CIDI-SC and DSM-IV/
SCID diagnoses of 30-day MDE (0.93), GAD (0.88), PD (0.90) and BPD (0.97), with only 9–38 questions needed to
administer all scales. CIDI-SC versus SCID prevalence diﬀerences are insigniﬁcant at the optimal CIDI-SC diagnostic
thresholds (x21=0.0–2.9, p=0.09–0.94). Individual-level diagnostic concordance at these thresholds is substantial (AUC
0.81–0.86, sensitivity 68.0–80.2%, speciﬁcity 90.1–98.8%). Likelihood ratio positive (LR+) exceeds 10 and LRx is 0.1
or less at informative thresholds for all diagnoses.
Conclusions. CIDI-SC operating characteristics are equivalent (MDE, GAD) or superior (PD, BPD) to those of the
best alternative screening scales. CIDI-SC results can be compared directly to general population CIDI survey results
or used to target and streamline second-stage CIDIs.
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Introduction
Although research on the community epidemiology of
mental disorders (i.e. general population incidence,
prevalence, risk factors, consequences) is an active
area of investigation (Susser et al. 2006; Kessler &
U¨stu¨n, 2008b ; Tsuang et al. 2011), research on clinical
epidemiology (i.e. prevalence, severity, long-term
course in treatment samples) is underdeveloped,
especially in primary care settings. Indeed, the most
important clinical epidemiological study of mental
disorders in primary care remains the World Health
Organization (WHO) Collaborative Study on Psycho-
logical Problems in General Health Care (U¨stu¨n
& Sartorius, 1995), a study carried out nearly two
decades ago that led to few extensions (e.g. Wittchen
et al. 2002; Barkow et al. 2003; Kisely & Simon, 2005 ;
* Address for correspondence : R. C. Kessler, Ph.D., Department of
Health Care Policy, Harvard Medical School, 180 Longwood Avenue,
Boston, MA 02115, USA.
(Email : Kessler@hcp.med.harvard.edu)
Psychological Medicine, Page 1 of 13. f Cambridge University Press 2012
doi:10.1017/S0033291712002334
ORIGINAL ARTICLE
Kisely et al. 2006). More sustained long-term clinical
epidemiological studies exist in specialty treatment
samples (Katz et al. 1979; Bruce et al. 2005), but those
studies are now outdated because of changes in the
composition of patient populations since the studies
were initiated (Kessler et al. 2005).
We know from primary care screening studies that
untreated mental disorders are common in primary
care (Lowe et al. 2008; Gili et al. 2011). However,
screening studies tell us little about the natural history
of these disorders, as screening studies typically focus
on current prevalence or treatment response. Yet
information is needed on episode recurrence and
onset of secondary disorders to understand the public
health signiﬁcance and long-term cost-eﬀectiveness of
primary care screening, outreach and treatment qual-
ity improvement (Barrett et al. 2005; Konnopka et al.
2009). This integration of primary care with public
health is now an area of considerable policy interest
(Committee on Integration to Improve Population
Health, 2012).
One way to build a critical mass of such data would
be to blend longitudinal clinical epidemiological
studies with community epidemiological surveys. For
example, several new community epidemiological
surveys in the WHO World Mental Health (WMH)
Survey Initiative (Kessler & U¨stu¨n, 2008a) are using a
dual-frame sampling approach with parallel samples
of (i) patients in primary care (both with and without
detected and undetected mental disorders) and
(ii) other household residents in the same communi-
ties. This design facilitates comparisons of illness
prevalence course among treated and untreated cases
by collecting successive snapshots of current preva-
lence of disorders over multiple points in time.
Screening scales will be used in the primary care
segment of these surveys as the ﬁrst stage in a two-
stage approach to oversample patients with current
mental disorders for second-stage interviews.
Screening scale responses are being ‘preloaded’ in the
computerized scripts of the second-stage interviews to
control question skip logic (e.g. skipping sections
based on negative screening responses ; expanding
questions based on positive screening responses). The
screening scales used for this purposes are based on
the WHO Composite International Diagnostic
Interview (CIDI ; Kessler & U¨stu¨n, 2004), the diagnos-
tic interview used in the WMH surveys and most
other psychiatric epidemiological surveys throughout
the world. Psychometric analyses of these disorder-
speciﬁc CIDI screening scales (CIDI-SC) have been
reported previously for adult attention deﬁcit/hyper-
activity disorder (ADHD; Kessler et al. 2007), insom-
nia, (Kessler et al. 2010a) and overall serious mental
illness (SMI; Kessler et al. 2010b). The current report
presents comparable results for the CIDI-SC scales of
major depressive episode (MDE), bipolar disorder
(BPD), generalized anxiety disorder (GAD) and panic
disorder (PD). Although the results presented are for
cross-sectional rather than longitudinal analyses, they
are relevant for the longitudinal design described
above because the latter is made up of a series of cross-
sectional snapshots.
Method
Screening scale development
The CIDI
The CIDI is a fully structured research diagnostic
interview developed for use by trained lay inter-
viewers to generate diagnoses of lifetime and recent
DSM-IV-TR/ICD-10 disorders (Robins et al. 1988).
Clinical reappraisal studies document generally good
concordance of CIDI diagnoses with blinded clinical
diagnoses (Wittchen, 1994 ; Kessler et al. 1998). The
CIDI uses extensive skip logic to reduce interview
length. This skip logic is also used in the CIDI-SC
based on the assumption that tablet computers will be
used to administer, score and print out summary
screening scale results.
Expanding the CIDI item pool
All CIDI symptom questions operationalize DSM/ICD
criteria using simple descriptive language (Robins
et al. 1988). However, validation studies ﬁnd some
CIDI questions less concordant than others with in-
dependent clinical assessments (Wittchen et al. 1995;
Kessler et al. 2006; Green et al. 2011). We consequently
expanded the CIDI item pool in developing the
CIDI-SC scales by reviewing a wide range of other
diagnostic instruments to generate alternative symp-
tom questions. The expanded question set was re-
viewed iteratively, with diagnostic experts using their
judgment to pinpoint alternative questions they con-
sidered potentially useful and to help revise and
prioritize indicators. Previous methodological re-
search has shown that such iterative expert review is
often the most useful form of pretesting (Converse &
Presser, 1986 ; Presser & Blair, 1994 ; Groves et al. 2009).
Pilot testing
Once preliminary symptom questions were generated,
a convenience sample of 15 psychiatric out-patients
with each diagnosis was administered the disorder-
speciﬁc symptom questions. Cognitive debrieﬁng
interviews (Willis, 2005) assessed problems in con-
ceptual understanding and question wording. These
interviews were conducted by professional cognitive
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interviewers using the ‘ think aloud’ method (Presser
et al. 2004) to elicit initial respondent reactions and
collect alternative terminologies for confusing phrases.
The results were presented to the diagnostic experts
for review and ﬁnal question revision.
The clinical reappraisal study
The sample
The revised questions were then administered to 3058
patients sampled from 29 primary care oﬃces selected
to include practices in both urban and rural areas in all
four US Census Regions (Northeast, South, Midwest
and West). No other stratiﬁcation criteria were used in
selecting practices. Practices were recruited through
the Primary Care Network (www.primarycarenet.
org). The original sample design called for a quota
sample of 100 completed interviews in each of 30
oﬃces with an unselected consecutive sample of
patients. This sample size was selected to allow for the
second-stage assessment of at least 30 screened
positives for even the least common disorder (BPD)
assuming plausible prevalence estimates and second-
stage response rates. However, because one selected
oﬃce dropped out after oﬃce recruitment ended,
other oﬃces in the same sample stratum were asked to
continue data collection for 2 days beyond the time
they met their quota, yielding a sample slightly larger
than the originally targeted 3000 and based on 29,
not 30, oﬃces.
Respondent recruitment began by giving a ‘study
fact brochure ’ to patients as they checked in that
explained the study as a test of a new screening ques-
tionnaire for common anxiety and mood disorders.
The brochure explained that the study needed people
aged o18 years both with and without the disorders
to complete a 15-min laptop computer questionnaire
in the waiting room; that participants would be re-
munerated US$25; that some participants would be
asked to participate in a telephone follow-up inter-
view that could take up to 1 h to complete ; and that
telephone respondents would receive an additional
US$50. The brochure emphasized that responses were
conﬁdential and decisions about participation would
not aﬀect health-care treatment or beneﬁts. Patients
who informed the oﬃce receptionist that they were
interested in the study then provided written in-
formed consent and received a laptop computer to
complete the questionnaire in the waiting room.
Telephone numbers provided in the questionnaire
were used to contact respondents and administer
clinical reappraisal interviews within 3 days of the
visit. The Human Subjects Committee of the New
England Institutional Review Board (www.neirb.com)
approved these recruitment, consent and ﬁeld pro-
cedures.
The clinical reappraisal interview
Each CIDI-SC respondent was classiﬁed as ‘very like-
ly ’, ‘ likely’, ‘possible ’ or ‘no’ on each screening scale.
A probability subsample of 30 respondents classiﬁed
‘very likely’ and 20 classiﬁed ‘ likely-possible ’ was
selected for each scale with replacement and admin-
istered the clinical reappraisal interview. The sampling
fraction varied across disorders due to prevalence
diﬀerences to make the sample well-distributed
across practices. Fifty patients who screened ‘no’
on all screening scales were also interviewed. The
total clinical reappraisal sample of 206 is less than
50r5=250 because some respondents were inde-
pendently selected for multiple disorders.
The clinical interview was an abridged Research
Version, Non-Patient Edition of the Structured Clinical
Interview for DSM-IV (SCID-I ; First et al. 2002)
focused on the four syndromes under study: 30-day
MDE and GAD and lifetime and 30-day PD and
mania/hypomania. Experienced SCID interviewers
administered the interviews under the supervision of
a study collaborator (P.E.K.) blinded to CIDI-SC re-
sponses. 30-day PD was deﬁned as lifetime PD with
30-day panic attacks and/or persistent concern
about additional attacks, worry about implications/
consequences of attacks, or signiﬁcant change in be-
havior due to attacks. 30-day BPD was deﬁned as
lifetime mania/hypomania with either 30-day MDE or
30-day mania/hypomania. SCID diagnoses were
made without diagnostic hierarchy rules but with
organic exclusions. Organic exclusions were not made
in the screening scales. Each SCID disorder was
classiﬁed as severe or non-severe to determine whe-
ther CIDI-SC could diﬀerentially detect more severe
cases. BP-I versus BP-II deﬁned BPD severity whereas
the distinction between severe and non-severe cases of
the other disorders was based on SCID interviewer
assessments of whether there were (i) many symptoms
more than needed for diagnosis, (ii) several symptoms
that were particularly severe and/or (iii) marked
impairment in social or occupational functioning
associated with the disorder.
Analysis methods
The clinical reappraisal sample was weighted to adjust
for oversampling of patients screened as ‘very likely’,
‘ likely ’ or ‘possible ’. Iterative stepwise logistic re-
gression was then used (0.05-level entry criterion) to
predict SCID diagnoses from CIDI-SC symptoms to
determine the minimum CIDI-SC question set needed
to approximate SCID diagnoses. An unweighted
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summary CIDI-SC score was created for each
diagnosis from this minimum symptom set and re-
ceiver operating characteristic curve (ROC) analysis
(Margolis et al. 2002) was used to estimate the area
under the ROC curve (AUC) for each scale. The AUC
is the probability of correctly identifying SCID cases
from CIDI-SC scores in paired comparisons of ran-
domly selected pairs of SCID cases and non-cases,
where CIDI-SC tied scores are assigned a 50% chance
of correct classiﬁcation (Kraemer, 1992). The AUC has
a predicted value of 0.5 when the screening scale is
completely unrelated to the true score and 1.0 when
perfectly related. CIDI-SC scores were not weighted to
avoid overﬁtting in the absence of a large enough
sample for cross-validation.
Each CIDI-SC score was then collapsed so that SCID
prevalence estimates increased monotonically across
screening scale strata but did not diﬀer signiﬁcantly
within strata using the logic of stratum-speciﬁc likeli-
hood ratio (LR) analysis (Pepe, 2003). McNemar
x2 tests then tested the signiﬁcance of diﬀerences be-
tween CIDI-SC and SCID prevalence estimates.
Signiﬁcance tests were based on Taylor series design-
based standard errors to adjust for data weighting
(Wolter, 1985).
Individual-level concordance was evaluated using
the AUC and Cohen’s k (Cohen, 1960). Although k is
the traditional measure used in psychiatric research,
it is not emphasized here because is varies across
populations that diﬀer in prevalence even when sen-
sitivity (SN; the percentage of true cases correctly
classiﬁed) and speciﬁcity (SP; the percentage of true
non-cases correctly classiﬁed) are constant (Cook,
1998). The AUC, in comparison, is a function of SN
and SP, which are considered the fundamental par-
ameters of agreement. The AUC equals (SN+SP)/2
when the screen is dichotomous. AUC scores between
0.5 and 1.0 are often interpreted in parallel with k as
slight (AUC=0.5–0.6, k=0.0–0.2), fair (AUC=0.6–0.7,
k=0.2–0.4), moderate (AUC=0.7–0.8, k=0.4–0.6),
substantial (AUC=0.8–0.9, k=0.6–0.8) and almost
perfect (AUCo0.9, ko0.8) (Landis & Koch, 1977). We
also report total classiﬁcation accuracy (TCA), the
proportion of all respondents whose CIDI-SC and
SCID classiﬁcations are consistent.
In addition, we report disaggregated measures
of operating characteristics, including SN and SP,
positive predictive value (PPV; proportion of screened
positives conﬁrmed by the SCID), negative predictive
value (NPV; proportion of screened negatives con-
ﬁrmed as non-cases by the SCID), LR positive [(LR+) ;
SN/(1 – SP)] and LR negative [LR–; (1 – SN)/SP)].
LR+ and LRx assess the relative proportions of
screened positives versus screened negatives con-
ﬁrmed as cases (LR+) or non-cases (LR–). LR+ values
o5 and LRx values f0.2 are generally considered
useful, whereas LR+ values o10 and LRx values
f0.1 are considered suﬃcient to rule in/out diag-
noses (Haynes et al. 2006).
Comparison with other widely used screening scales
To compare CIDI-SC operating characteristics with
other screening scales, a 1990–2012 Medline search of
screening scale validity studies was carried out using
search terms ‘screening’, ‘validity ’, ‘ sensitivity ’,
‘ speciﬁcity ’, ‘case ﬁnding’ and ‘AUC’ crossed with
‘depression’, ‘bipolar disorder ’, ‘manic depression’,
‘generalized anxiety disorder ’ and ‘panic disorder ’.
We focused on studies where screening scales were
compared to blinded clinical reappraisal interviews in
samples of patients, community residents or internet
users. Only key studies were considered.
Results
Stepwise logistic regression
Separate stepwise logistic regression analyses were
used to predict each SCID disorder from the corre-
sponding CIDI screening items.
MDE
Three CIDI questions were entered stepwise to pre-
dict 30-day dysphoria (sad–depressed, down–
discouraged) and anhedonia (little–no interest in
day-to-day activities) in the total sample. Among re-
spondents with dysphoria and/or anhedonia, ﬁve
additional questions were entered to screen for other
DSM-IV Criterion A symptoms of MDE or the
Criterion C requirement of clinically signiﬁcant dis-
tress or impairment. The AUC for the continuous
CIDI-SC scale with these eight questions was 0.93.
GAD
Two CIDI questions were entered to screen for 30-day
DSM-IV GAD Criterion A (excessive anxiety–worry
about multiple events–activities) in the total sample.
Among Criterion A screened positives, ﬁve additional
questions were entered to screen for Criteria B
(diﬃculty controlling worry), C (restless, diﬃculty re-
laxing) and E (clinically signiﬁcant distress or im-
pairment). The AUC for the continuous CIDI-SC scale
with these seven questions was 0.88.
PD
Two CIDI questions were entered to screen for having
lifetime attacks of intense fear or discomfort that
came on very suddenly in the total sample. Among
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respondents with such attacks, seven follow-up
questions were entered about psycho-physiological
symptoms. Among patients with such symptoms, an
additional question asked about symptoms reaching a
peak within 10 min and two question asked about the
Criterion A1 DSM-IV PD requirement that attacks be
recurrent and unexpected. Four questions asked about
Criterion A2 that attacks be followed by a month of
persistent concern about another attack, worry about
implications or signiﬁcant change in behavior. Final
questions then asked about 30-day prevalence. The
AUC for the continuous CIDI-SC scale with these
15 symptom questions crossed with reports of 30-day
recency was 0.90.
BPD
Two CIDI questions were entered to screen for life-
time DSM-IV mania-hypomania Criterion A (distinct
periods of abnormally persistently elevated, expansive
or irritable mood) in the total sample. Among re-
spondents who endorsed at least one such question,
four additional questions were entered to screen
for Criterion B (more talkative than usual, racing
thoughts, psychomotor agitation, excessive involve-
ment in activities having high potential for painful
consequences) and two for Criterion D (mania)/E
(hypomania) involving presence–absence of marked
impairment or hospitalization. A ﬁnal question then
asked about 30-day prevalence. The AUC for the con-
tinuous CIDI-SC scale with these eight questions
for lifetime or 30-day mania–hypomania crossed with
the CIDI-SC screen for 30-day MDE to deﬁne 30-day
BPD was 0.97.
The three CIDI-SC diagnostic stem questions for
MDE combined with two for GAD, two for PD and
two for BPD create a set of only nine items that screen
out the majority of primary care patients in less than
3 min. The maximum number of items (40) can be
completed in no more than 8 min.
Concordance of DSM-IV CIDI-SC and SCID
diagnoses
CIDI-SC versus SCID prevalence estimate diﬀerences
are insigniﬁcant for all disorders at optimal (for esti-
mating prevalence) CIDI-SC thresholds (x21=0.0–2.9,
p=0.09–0.98) (Table 1). Aggregate diagnostic con-
cordance at these thresholds is substantial for all dis-
orders (AUC=0.81–0.86), with proportions of SCID
cases detected (SN) of 68.0–80.2%. The proportions
of SCID non-cases classiﬁed correctly (SP) are 90.1–
98.8%. Lower SN than SP is expected for thresholds
designed to estimate prevalence without bias when
only a minority of patients has a disorder, in which
case LR+ is more informative than SN. LR+ is >10
for three of the four CIDI-SC at the optimal thresholds,
indicating that screened positives are much more
likely than screened negatives to be conﬁrmed as SCID
cases. LR+ is 8.1 for MDE, an informative but not
deﬁnitive value. The proportions of screened positives
at the optimal thresholds conﬁrmed as SCID cases
(PPV) are in the range 48.2% (GAD) to 73.7% (BPD)
(Table 2).
The screen for MDE, the only one where LR+ is
<10, can be made more conservative by raising the
threshold (LR+=24.5, PPV=85.9%), but at the cost of
reducing SN from 80.2% to 46.5%. All four CIDI-SC
can be made less conservative by lowering their
thresholds, increasing SN to between 94.8% (BPD) and
100% (GAD and PD), but at the cost of increasing the
estimated prevalence and decreasing LR+ and PPV.
The only disorder where this conservative change is
eﬃcient is BPD, with an estimated prevalence
Table 1. Consistency of DSM-IV diagnoses based on the CIDI screening scales (CIDI-SC) at their optimal (to estimate prevalence)
thresholds and based on the SCID (n=206)
CIDI-SC SCID
McNemara
% (S.E.) % (S.E.) x21 AUC k TCA SN (S.E.) SP (S.E.)
MDE 23.8 (3.5) 19.7 (3.3) 2.9 0.85 0.65 88.2 80.2 (7.6) 90.1 (2.5)
GAD 10.8 (1.7) 7.7 (1.7) 2.5 0.81 0.52 91.9 68.0 (10.0) 93.9 (1.2)
PD 13.7 (2.6) 10.7 (2.5) 2.4 0.85 0.62 91.9 76.4 (10.3) 93.8 (1.4)
BPD 4.4 (1.0) 4.4 (1.2) 0.0 0.86 0.73 97.7 74.0 (13.8) 98.8 (0.5)
CIDI, Composite International Diagnostic Interview ; SCID, Structured Clinical Interview for DSM-IV ; AUC, area under
the receiver operating characteristic curve ; TCA, total classiﬁcation accuracy ; SN, sensitivity of the screening scale at the
designated threshold ; SP, speciﬁcity of the screening scale at the designated threshold ; MDE, major depressive episode ;
GAD, generalized anxiety disorder ; PD, panic disorder ; BPD, bipolar disorder ; S.E., standard error.
a Prevalence estimates based on the CIDI-SC do not diﬀer signiﬁcantly from those based on the SCID for any of the diagnoses
(p=0.09–0.98).
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increasing from 4.4% to 7.0%, LR+ and PPV both re-
maining high (31.6, 59.1%) and SN increasing from
74.0% to 94.8%.
Although SP is above 90% for all disorders, this
is not a deﬁnite rule-out when only a small minority of
respondents has the disorder, in which case LRx is
more informative. LRx isf0.2 for only two diagnoses
at the optimal threshold (MDE and PD) whereas LRx
is never below 0.2, meaning that none of the diagnoses
can be ruled out conﬁdentlywithCIDI-SC scores below
the optimal diagnostic threshold. However, thresholds
can be lowered to produce LRx values less than 0.1 for
all disorders, although at the cost of reducing SN.
For MDE, 54.1% of patients can be ruled out [i.e. at
a threshold where 45.9% (100%–45.9%=54.1%) of
patients screen positive] with LRx 0.1 (NPV=99.7%).
For GAD, 55.7% of patients can be ruled out with
LRx 0.0 (NPV=100%). For PD, 86.3% of patients can
be ruled out with LRx 0.2 and 37.9% with LRx 0.0.
None of the PD screened negatives at the lower
thresholds and 2.8% at the next lowest threshold had a
SCID diagnosis. For BPD, 93% of patients can be ruled
out with LRx 0.1 (NPV=99.8%).
Severe and non-severe cases
SN is higher for severe than non-severe cases of
all four diagnoses at the optimal threshold (Table 3).
SN is 85.4–92.9% for severe MDE, PD and BPD versus
68.9–69.6% for non-severe cases and 70.8% versus
59.6% for severe and non-severe GAD. However, none
of the severe versus non-severe SN diﬀerences are
statistically signiﬁcant because of the small numbers
of cases (x21=0.2–2.4, p=0.12–0.68).
Comparisons with other screening scales
MDE
The nine-item Patient Health Questionnaire (PHQ-9;
Spitzer et al. 1999) is the most widely used major
depression screening scale. Reviews of many PHQ-9
primary care validity studies (Gilbody et al. 2007;
Wittkampf et al. 2007; Kroenke et al. 2010; Manea
et al. 2012) show a central tendency of the AUC to
be 0.85–0.88, which does not diﬀer meaningfully from
the CIDI-SC MDE AUC of 0.85. (See online Appendix
Tables 1–4 for detailed results.) CIDI-SC SN and SP
(0.80, 0.90) are also in the middle of the PHQ-9 ranges
(0.77–0.88, 0.88–0.94). The AUC of other MDE screen-
ing scales is generally lower (0.72–0.84) and LR+ un-
informative (Zigmond & Snaith, 1983 ; Broadhead et al.
1995; Farvolden et al. 2003; Hunter et al. 2005; Donker
et al. 2009; Gaynes et al. 2010; Houston et al. 2011). One
exception was found in a community survey of the
Center for Epidemiologic Studies Depression scale
(CES-D; Radloﬀ, 1977), with an AUC of 0.94 (Beekman
et al. 1997), but other CES-D validity studies found
considerably lower AUC, at 0.76–0.82 (Schulberg et al.
1985; Klinkman et al. 1997; Thomas et al. 2001).
Table 2. CIDI screening scale (CIDI-SC) classiﬁcation of DSM-IV/SCID cases and non-cases at diﬀerent thresholds
on the CIDI-SC (n=206)a
p (S.E.) SN (S.E.) LR+ PPV (S.E.) SP (S.E.) LRx NPV (S.E.)
I. MDE
Conservative 10.7 (1.9) 46.5 (8.3) 24.5 85.9 (4.6) 98.1 (0.6) 0.5 88.2 (3.2)
Optimal 23.8 (3.5) 80.2 (7.6) 8.1 66.5 (7.0) 90.1 (2.5) 0.2 94.9 (2.2)
Anti-conservative 45.9 (4.7) 99.2 (0.8) 3.0 42.6 (6.1) 67.2 (5.1) 0.0 99.7 (0.3)
II. GAD
Optimal 10.8 (1.7) 68.0 (10.0) 11.1 48.2 (6.7) 93.9 (1.2) 0.3 97.2 (1.4)
Anti-conservative 44.3 (4.9) 100 (–) 2.5 17.3 (3.7) 60.3 (5.2) 0.0 100 (–)
III. PD
Optimal 13.7 (2.6) 76.4 (10.3) 12.3 59.5 (8.6) 93.8 (1.4) 0.2 97.1 (1.4)
Anti-conservative 62.1 (4.9) 100 (–) 1.7 17.2 (4.0) 42.5 (5.2) 0.0 100 (–)
IV. BPD
Optimal 4.4 (1.0) 74.0 (13.8) 61.7 73.7 (9.0) 98.8 (0.5) 0.3 98.8 (0.8)
Anti-conservative 7.0 (1.8) 94.8 (3.4) 31.6 59.1 (13.4) 97.0 (1.4) 0.1 99.8 (0.2)
CIDI, Composite International Diagnostic Interview ; SCID, Structured Clinical Interview for DSM-IV ; p, proportion
of patients who screened positive on the CIDI-SC at the designated threshold ; SN, sensitivity of the CIDI-SC at the designated
threshold ; LR+, likelihood ratio positive of the CIDI-SC at the designated threshold ; PPV, positive predictive value of the
CIDI-SC at the designated threshold ; SP, speciﬁcity of the CIDI-SC at the designated threshold ; LRx, likelihood ratio negative
of the CIDI-SC at the designated threshold ; NPV, negative predictive value of the CIDI-SC at the designated threshold ; MDE,
major depressive episode ; GAD, generalized anxiety disorder ; PD, panic disorder ; BPD, bipolar disorder ; S.E., standard error.
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GAD
The CIDI-SC GAD AUC (0.81) is in the middle of the
range for the GAD screening scales reviewed (0.74–
0.85) (Broadhead et al. 1995; Farvolden et al. 2003;
Kroenke et al. 2007; Donker et al. 2009, 2011; Houston
et al. 2011). However, CIDI-SC SN and SP (0.68, 0.94)
are closest to those of one specialty treatment screen-
ing scale, the Web-Based Depression and Anxiety Test
(WB-DAT; Farvolden et al. 2003). Other screening
scales have higher SN (0.83–0.93) but much lower
SP (0.45–0.82). CIDI-SC and WB-DAT consequently
have much higher LR+ (11.1, 10.5) than other scales
(1.7–4.9), indicating higher conﬁrmation of screened
positives. This can be illustrated using Bayes’ theorem
to calculate post-test probability of SCID GAD for
screened positives (Altman & Bland, 1994), which
shows that for a true GAD prevalence of 5–15%, con-
ﬁrmation of screened positives would be only 21–46%
for screening scales but much higher for WB-DAT
(36–65%) and CIDI-SC (37–66%). Caution is needed in
interpreting the WB-DAT results, however, as they
were obtained in a specialty treatment setting.
PD
The CIDI-SC PD AUC (0.85) is at the upper end of the
PD screening scales reviewed (0.69–0.88) (Broadhead
et al. 1995; Stein et al. 1999; Farvolden et al. 2003; Lowe
et al. 2003; Hunter et al. 2005; Bunevicius et al. 2007;
Kroenke et al. 2007; Donker et al. 2009). CIDI-SC has
among the highest LR+ (12.3) along with WB-DAT
(12.5) and one of two GAD-7 (19.0) validity studies
(Lowe et al. 2003). The high LR+ in that GAD-7 study,
however, is oﬀset by a much lower LR+ (3.9) in a se-
cond much larger GAD-7 study (Kroenke et al. 2007).
The scales with high LR+ are much more distinct for
their high SP (0.94–0.96) than high SN. If we assume
that the true PD prevalence is in the range 5–15% in
primary care and SN–SP estimates are accurate, con-
ﬁrmation of screened positives would be 35–65% for
CIDI-SC andWB-DAT, 17–77% for the GAD-7, and no
higher than 20–45% for other screening scales.
BPD
Although the Mood Disorder Questionnaire (MDQ;
Hirschfeld et al. 2000) is by far the most widely used
BPD screening scale, the vast majority of MDQ studies
focus on patients in treatment for depression and
investigate whether those with BPD can be dis-
tinguished from non-bipolar depressives (Hirschfeld
et al. 2000, 2005 ; Miller et al. 2004, 2011 ; Weber Rouget
et al. 2005; Parker et al. 2008, 2012 ; Twiss et al. 2008;
Zimmerman et al. 2009). This focus reﬂects the fact
that the MDQ was developed to address the under-
detection of BPD among depressed patients
(Hirschfeld & Vornik, 2004). We are aware of only
two MDQ validity studies that evaluated ability to
distinguish patients with BPD from all other patients
(including those without depression) in settings other
than a specialty clinic (Hirschfeld et al. 2003; Dodd
et al. 2009). These studies were both carried out in
community samples. The MDQ AUCwas fairly low in
both studies (AUC=0.62) compared to much higher
AUCs (0.86–0.96) for the CIDI-SC BPD scale at its two
informative thresholds.
Only one other BPD screening scale, the Mood
Swings Questionnaire (MSQ; Parker et al. 2006), had
an AUC as high as the CIDI-SC, but this was in a study
in a mental health specialty clinic among patients
presenting for treatment of depression. Two sub-
sequent studies in that same clinic produced lower
MSQ AUC estimates (0.73–0.81 ; Parker et al. 2008,
2012). Other BPD screening scales reviewed had lower
AUC (0.66–0.81 ; Hunter et al. 2005; Gaynes et al. 2010).
Table 3. CIDI screening scale (CIDI-SC) sensitivity (SN) and likelihood ratio positive (LR+) for detecting severe and non-severe
DSM-IV/SCID cases (n=206)
Severe Non-severe Total Severe v.
non-severea
SN (S.E.) LR+ SN (S.E.) LR+ SN (S.E.) LR+ x21
MDE 92.9 (4.1) 9.4 69.6 (12.6) 7.0 80.2 (7.6) 8.1 2.1
GAD 70.8 (15.2) 11.6 59.6 (14.7) 9.8 68.0 (11.7) 11.1 0.2
PD 90.8 (7.5) 14.6 68.9 (14.7) 11.1 76.4 (10.3) 12.3 2.3
BPD 85.4 (10.0) 71.2 69.0 (18.6) 57.5 74.0 (13.8) 61.7 2.4
CIDI, Composite International Diagnostic Interview ; SCID, Structured Clinical Interview for DSM-IV ; SN, sensitivity of the
CIDI-SC at the designated threshold ; LR+, likelihood ratio positive of the CIDI-SC at the designated threshold ; MDE, major
depressive episode ; GAD, generalized anxiety disorder ; PD, panic disorder ; BPD, bipolar disorder ; S.E., standard error.
a Although SN is consistently higher for severe than non-severe cases, none of these diﬀerences is statistically signiﬁcant
(p=0.12–0.68).
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The advantage of CIDI-SC over these other scales can
be traced to high CIDI-SC SN at its anti-conservative
threshold (0.95). Although, as noted earlier, high SN
is often accompanied by low LN+, this is not the case
with CIDI-SC BPD, where LR+ is 31.6 at the anti-
conservative threshold and 62–85% of screened posi-
tives would be conﬁrmed as SCID cases if the true BPD
prevalence was in the range 5–15%.
Discussion
CIDI-SC operating characteristics are equivalent to
the best alternative screening scales for MDE and
GAD and superior to other screening scales for PD and
BPD. CIDI-SC results can be compared directly to
general population epidemiological CIDI surveys be-
cause CIDI-SC items all come from the CIDI. Such
nested screening scales can be useful in targeting
and streamlining CIDI follow-up interviews by ‘pre-
loading’ CIDI-SC responses into the CIDI computer-
ized interview program to guide interview question
skip logic. Such an integrated computerized CIDI
interviewing system is currently in development
and includes options for self-administering CIDI-SC
on tablet computers in primary care waiting rooms,
web-based CIDI-SC self-administration to track treat-
ment response, and interviewer-based CIDI interview
administration using pre-loaded CIDI-SC responses.
The fact that AUCs of continuous CIDI-SC scales
in ROC analyses (0.88–0.97) are considerably higher
than AUCs of dichotomized CIDI-SC scales at their
unbiased thresholds (0.81–0.86) means that meaning-
ful variation in SCID prevalence exists throughout
the CIDI-SC scale ranges. One implication, as shown
in the comparative analyses of LR+ and LRx at
multiple thresholds, is that diﬀerent thresholds can
be useful for screening in than screening out cases.
Importantly, the CIDI-SC has excellent LR+ and LRx
at multiple informative thresholds. Furthermore,
continuous CIDI-SC scores can be converted into pre-
dicted probabilities of clinical diagnoses in epidemio-
logical studies to yield more accurate estimates of
prevalence than by dichotomizing scores and classi-
fying each respondent as either a deﬁnite case or
a non-case. This predicted probability approach is
discussed in more detail elsewhere (Kessler et al.
2010b).
Despite these positive ﬁndings, several study
limitations are noteworthy. First, CIDI-SC SN is
lower for GAD than other diagnoses. Disaggregation
shows that this is because CIDI-SC have diﬃculty op-
erationalizing the DSM-IV requirement that worries
be excessive. CIDI-SC questions for this requirement
have a higher threshold than the SCID. A similar result
was found in an earlier study of the full CIDI
(Wittchen et al. 1995). Concerns exist about clinician
ability to determine when worries are excessive
(Ruscio et al. 2005), leading to the suggestion that
more concrete guidance be given in DSM-5 about de-
ﬁning excessiveness (Andrews et al. 2010). Although
such guidance does not appear in currently proposed
DSM-5 criteria (www.dsm5.org/ProposedRevisions),
new behavioral requirements (proposed DSM-5
Criterion D) of marked avoidance, time–eﬀort, pro-
crastination or seeking reassurance might help to
establish a threshold for excessiveness that could be
the basis for improving revised CIDI-SC GAD SN.
Second, although we want to use CIDI-SC results to
create a cross-walk between general population CIDI
epidemiological surveys and primary care CIDI-SC
screening studies, no guarantee exists that CIDI-SC
operating characteristics will be similar in community
epidemiological surveys and primary care samples.
It is consequently important to include CIDI-SC in
future CIDI community surveys and validate their
operating characteristics relative to diagnoses based
on the full CIDI and SCID. Such methodological
studies are currently underway in new CIDI surveys
in the WHOWMH Survey Initiative (Kessler & U¨stu¨n,
2008a).
Third, our clinical reappraisal sample was relatively
small because of funding limitations, precluding
cross-validation, subgroup analysis, or analysis of
information values across the range of continuous
CIDI-SC scores to evaluate sensitivity to change. These
limitations make it especially important to replicate
the current study in independent primary care
samples, to investigate the stability of the encouraging
results reported here and to carry out analyses of
the clinical sensitivity of variation in continuous CIDI-
SC scores to assess the severity of anxiety and de-
pression. Larger replication studies could also help to
establish an empirical foundation for determining
whether even shorter versions of CIDI-SC might be
developed based on computerized adaptive testing
(Gibbons et al. 2011).
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